Ghent, BELGIUM – 27 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the Annual and Extraordinary General Meeting of Shareholders were approved at the meetings held […]
Author: Ken Dropiewski
InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq
Tickers to be NSPRW and NSPRZ TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently […]
FEops HEARTGuide Combines Digital Twins and AI to Revolutionize Structural Heart Planning
GENT, Belgium–(BUSINESS WIRE)–FEops strengthens its position as the cloud-based digital health player in the structural heart space by introducing Artificial Intelligence into its CE marked FEops HEARTguide platform. FEops HEARTguide is a one-in-its-kind procedure planning platform for structural heart interventions that provides physicians with unique insights to evaluate device sizing and positioning pre-operatively. The […]
Scientia Raises $50M Growth Equity Investment from Vivo Capital
SALT LAKE CITY–(BUSINESS WIRE)–Scientia Vascular (“Scientia” or the “Company”), a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices, has raised $50M of growth equity financing from Vivo Capital, a Palo Alto, CA-headquartered global healthcare investment firm. The financing will be used […]
Varian Receives FDA “Breakthrough Device Designation” for its Cardiac Radioablation (CRA) System for Treatment of Refractory Ventricular Tachycardia (VT)
– Varian’s CRA system has been designated a “breakthrough device” by the FDA because of its potential to offer a more effective treatment for select patients with refractory VT. – Technology being developed will be assessed in clinical studies as a noninvasive treatment for select patients with refractory VT. PALO […]
Biobeat Launches Wearable Continuous Ambulatory Blood Pressure Monitoring (ABPM) Device
New Clinical Data Supports Use of Biobeat ABPM Cuffless-Monitor as Reliable and Accurate Solution for Out-of-Clinic Blood Pressure Monitoring PETAH TIKVA, Israel, May 26, 2021 /PRNewswire/ — Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today the launch of its new wearable and continuous ambulatory blood pressure […]
Mezzion’s New Drug Application (“NDA”) for its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease (“SVHD”) has been Accepted for Filing by the FDA
SEOUL, South Korea, May 25, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ) is pleased to announce today that it has received notice from the FDA that its NDA submitted on March 26, 2021 for the use of udenafil to treat SVHD patients who have undergone Fontan palliation is sufficiently complete to permit a substantive review […]
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
VANCOUVER and MINNEAPOLIS, May 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth […]
Hello Heart Completes $45M Investment to Fuel Growth and Expand Digital Heart Health
Series C financing was led by IVP and includes existing investors MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the best-in-class heart health digital therapeutics solution, has completed a $45 million Series C led by IVP. IVP is a top later-stage partner for hypergrowth companies including Coinbase, Lyra Health, Slack, Snap, Twitter, and […]
SIRONA – The world’s first and largest RCT comparing Sirolimus V/S Paclitaxel balloon for the treatment of Peripheral Arterial Disease progresses rapidly
JENA, Germany, May 24, 2021 /PRNewswire/ — Concept Medical Inc., focused on vascular intervention drug delivery devices, releases status updates of SIRONA Randomized Control Trial (RCT) which compares head-to-head, SIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in femoropopliteal arterial diseases (SIRONA). SIRONA is the world’s first RCT investigating the use of Sirolimus drug coated balloon (DCB) (MagicTouch PTA – Concept Medical) […]



